Lei Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lei Cheng has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Chao Zhao
Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University, Tongji University Medical School Cancer Institute, Shanghai 200433, China
4 shared publications Haowei Wang
4 shared publications- Xuefei Li
Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
4 shared publications Caicun Zhou
3 shared publicationsChao Zhao
3 shared publicationsXuefei Li
3 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2161
Dynamic Monitoring of CTCs and EVs to Predict Chemoimmunotherapy Efficacy in Lung Cancer
Background: Circulating tumor cells (CTCs), programmed cell death-ligand 1 (PD-L1) positive CTCs (PD-L1+CTCs) and extracellular vesicles (EVs) are important biomarkers for predicting treatment efficacy. This study comprehensively investigated the factors used to forecast chemoimmunotherapy efficacy in advanced lung cancer. Methods: The CellSearch system, EVAnalyzer plugin and single-cell whole-exome sequencing (WES) were used to analyze these factors. Results: It was found that CTCs were highly detectable in advanced lung cancer. The median number of baseline CTCs was significantly lower in non-small cell lung cancer (NSCLC) than small cell lung cancer (SCLC) (3 vs. 38, p < 0.0001), as were PD-L1+CTCs (1 vs. 5, p = 0.0014). PD-L1+CTCs decreasing after two treatment circles was associated with superior ORR. Baseline median EV counts were elevated in NSCLC compared with SCLC (11,700 vs 1371, p = 0.017). Patients exhibiting divergent dynamic trends between EVs and CTC/PD-L1+CTCs demonstrated better treatment response. The combination of CTCs, PD-L1+CTCs and EVs improved predictive efficacy for both NSCLC and SCLC. CTC sequencing identified multiple pathogenic somatic variants, which might affect immunotherapy efficacy. Conclusions: Serial dynamic monitoring of CTCs, PD-L1+CTCs and EVs, as well as CTC sequencing, enables the early prediction of chemoimmunotherapy response and the discovery of mechanisms that affect immunotherapy efficacy in advanced lung cancer.
- 24 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2161
Open AccessDynamic Monitoring of CTCs and EVs to Predict Chemoimmunotherapy Efficacy in Lung Cancer
Background: Circulating tumor cells (CTCs), programmed cell death-ligand 1 (PD-L1) positive CTCs (PD-L1+CTCs) and extracellular vesicles (EVs) are important biomarkers for predicting treatment efficacy. This study comprehensively investigated the factors used to forecast chemoimmunotherapy efficacy in advanced lung cancer. Methods: The CellSearch system, EVAnalyzer plugin and single-cell whole-exome sequencing (WES) were used to analyze these factors. Results: It was found that CTCs were highly detectable in advanced lung cancer. The median number of baseline CTCs was significantly lower in non-small cell lung cancer (NSCLC) than small cell lung cancer (SCLC) (3 vs. 38, p < 0.0001), as were PD-L1+CTCs (1 vs. 5, p = 0.0014). PD-L1+CTCs decreasing after two treatment circles was associated with superior ORR. Baseline median EV counts were elevated in NSCLC compared with SCLC (11,700 vs 1371, p = 0.017). Patients exhibiting divergent dynamic trends between EVs and CTC/PD-L1+CTCs demonstrated better treatment response. The combination of CTCs, PD-L1+CTCs and EVs improved predictive efficacy for both NSCLC and SCLC. CTC sequencing identified multiple pathogenic somatic variants, which might affect immunotherapy efficacy. Conclusions: Serial dynamic monitoring of CTCs, PD-L1+CTCs and EVs, as well as CTC sequencing, enables the early prediction of chemoimmunotherapy response and the discovery of mechanisms that affect immunotherapy efficacy in advanced lung cancer.
- Open Access
- 11 August 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 48
Evaluation of preoperative plasma cytokines for the diagnosis and prognosis of malignant lung nodules
- 11 August 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 48
Open AccessEvaluation of preoperative plasma cytokines for the diagnosis and prognosis of malignant lung nodules
- Open Access
- 29 May 2025
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 8, 25
ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC
Aim: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment approach for NSCLC. However, the effectiveness of ICI therapy in patients with EGFR-driven NSCLC, particularly those resistant to EGFR-TKI, has been disappointing. The immunosuppressive tumor microenvironment (TME) following EGFR-TKI therapy has been proved to significantly affected the effectiveness of ICIs. Therefore, studying the mechanism behind the development of a suppressive TME and exploring potential interventions is crucial for research on EGFR-TKI-resistant NSCLC. Methods: ZEB2 levels were quantified in human NSCLC cell lines and in tumor specimens from NSCLC patients by quantitative RT-PCR (qRT-PCR), WB, and immunohistochemical staining. To examine how ZEB2 affected macrophage polarization, M1/M2 marker profiles were measured with qRT-PCR and flow cytometry. Changes in cytokine production triggered by altered ZEB2 expression were determined with qRT-PCR, ELISA, and Meso Scale Discovery electrochemiluminescence assays. The direct binding of ZEB2 to cytokine-gene promoters was tested using a dual-luciferase reporter system. Upstream regulatory pathways were investigated by correlating LUAD transcriptomic data from TCGA with ZEB2 expression and validating key findings via western blotting. Finally, cell-derived xenograft (CDX) models were generated by subcutaneously implanting pre-treated PC9 or HCC827 cells into BALB/c nude mice to verify the impact of EGFR-TKI resistance and ZEB2 on tumor-associated macrophage (TAM) polarization in vivo . Results: It was elucidated that EGFR-TKI resistance upregulated the M2 polarization biomarkers, Arg-1 (PC9-GR: P < 0.01; HCC827-GR: P < 0.05) and IL4 (PC9-GR: P < 0.01; HCC827-GR: P < 0.01), while downregulated the M1 polarization biomarkers, TNF-α (PC9-GR: P < 0.01; HCC827-GR: P < 0.01), IL1β (PC9-GR: P < 0.01; HCC827-GR: P < 0.01), and IL6(PC9-GR: P < 0.001; HCC827-GR: P < 0.001) in NSCLC cell lines. Meanwhile, CD206+ TAMs (PC9-GR: P < 0.05; HCC827-GR: P < 0.01) were increased and CD86+ TAMs (PC9-GR: P < 0.05; HCC827-GR: P < 0.05) were decreased in both EGFR-TKI-resistant mice models. Apart from the formation of suppressive TME, ZEB2 was found to be upregulated in PC9-GR (qRT-PCR: P < 0.0001; WB: P < 0.05) and HCC827-GR (qRT-PCR: P < 0.0001; WB: P < 0.05) cells. The same trend was also noticed in clinical samples, with ZEB2 upregulated after gefitinib resistance in NSCLC patients (P < 0.0001). Based on these findings, ZEB2 knockdown was proved to downregulate Arg-1 (PC9-GR: P < 0.01; HCC827-GR: P < 0.05) and IL4 (PC9-GR: P < 0.01; HCC827-GR: P < 0.001), while upregulate the TNF-α (PC9-GR: P < 0.0001; HCC827-GR: P < 0.0001), IL1β (HCC827-GR: P < 0.001), and IL6 (PC9-GR: P < 0.01; HCC827-GR: P < 0.001), indicating its role in M1/M2 polarization in both EGFR-TKI-resistant NSCLC cell lines. The downregulation of CD206+ TAMs (PC9-GR: P < 0.05; HCC827-GR: P < 0.01) and the upregulation of CD86+ TAMs (PC9-GR: P < 0.001; HCC827-GR: P < 0.05) also demonstrated the reversion of suppressive TME after ZEB2 knockout in EGFR-TKI-resistant mice models. Additionally, after the intervention of MK2206, which was an Akt inhibitor, ZEB2 expression was suppressed at both low (PC9-GR: P < 0.001; HCC827-GR: P < 0.001) and high concentrations (PC9-GR: P < 0.001; HCC827-GR: P < 0.0001). Finally, the mechanism underlying ZEB2’s regulation on TAM polarization was proved to be associated with cytokine secretion. According to the results of ELISA, apart from its inducement on TGF-β1 secretion (PC9-GR: P < 0.0001; HCC827-GR: P < 0.0001), ZEB2 could directly bind to the promoter region of CSF-1 to elevate its secretion (PC9-GR: P < 0.0001; HCC827-GR: P < 0.0001). Conclusion: In EGFR-TKI-resistant NSCLC, activation of the PI3K-Akt cascade drove a marked rise in ZEB2 expression. The elevated ZEB2 increased CSF-1 and TGF-β1 release, steering macrophages toward an M2 phenotype while impeding M1 polarization. Accordingly, suppressing ZEB2 had the potential to reshape the TME and enhance the effectiveness of ICIs once EGFR-TKI resistance had emerged.
- 29 May 2025
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 8, 25
Open AccessZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC
Aim: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment approach for NSCLC. However, the effectiveness of ICI therapy in patients with EGFR-driven NSCLC, particularly those resistant to EGFR-TKI, has been disappointing. The immunosuppressive tumor microenvironment (TME) following EGFR-TKI therapy has been proved to significantly affected the effectiveness of ICIs. Therefore, studying the mechanism behind the development of a suppressive TME and exploring potential interventions is crucial for research on EGFR-TKI-resistant NSCLC. Methods: ZEB2 levels were quantified in human NSCLC cell lines and in tumor specimens from NSCLC patients by quantitative RT-PCR (qRT-PCR), WB, and immunohistochemical staining. To examine how ZEB2 affected macrophage polarization, M1/M2 marker profiles were measured with qRT-PCR and flow cytometry. Changes in cytokine production triggered by altered ZEB2 expression were determined with qRT-PCR, ELISA, and Meso Scale Discovery electrochemiluminescence assays. The direct binding of ZEB2 to cytokine-gene promoters was tested using a dual-luciferase reporter system. Upstream regulatory pathways were investigated by correlating LUAD transcriptomic data from TCGA with ZEB2 expression and validating key findings via western blotting. Finally, cell-derived xenograft (CDX) models were generated by subcutaneously implanting pre-treated PC9 or HCC827 cells into BALB/c nude mice to verify the impact of EGFR-TKI resistance and ZEB2 on tumor-associated macrophage (TAM) polarization in vivo . Results: It was elucidated that EGFR-TKI resistance upregulated the M2 polarization biomarkers, Arg-1 (PC9-GR: P < 0.01; HCC827-GR: P < 0.05) and IL4 (PC9-GR: P < 0.01; HCC827-GR: P < 0.01), while downregulated the M1 polarization biomarkers, TNF-α (PC9-GR: P < 0.01; HCC827-GR: P < 0.01), IL1β (PC9-GR: P < 0.01; HCC827-GR: P < 0.01), and IL6(PC9-GR: P < 0.001; HCC827-GR: P < 0.001) in NSCLC cell lines. Meanwhile, CD206+ TAMs (PC9-GR: P < 0.05; HCC827-GR: P < 0.01) were increased and CD86+ TAMs (PC9-GR: P < 0.05; HCC827-GR: P < 0.05) were decreased in both EGFR-TKI-resistant mice models. Apart from the formation of suppressive TME, ZEB2 was found to be upregulated in PC9-GR (qRT-PCR: P < 0.0001; WB: P < 0.05) and HCC827-GR (qRT-PCR: P < 0.0001; WB: P < 0.05) cells. The same trend was also noticed in clinical samples, with ZEB2 upregulated after gefitinib resistance in NSCLC patients (P < 0.0001). Based on these findings, ZEB2 knockdown was proved to downregulate Arg-1 (PC9-GR: P < 0.01; HCC827-GR: P < 0.05) and IL4 (PC9-GR: P < 0.01; HCC827-GR: P < 0.001), while upregulate the TNF-α (PC9-GR: P < 0.0001; HCC827-GR: P < 0.0001), IL1β (HCC827-GR: P < 0.001), and IL6 (PC9-GR: P < 0.01; HCC827-GR: P < 0.001), indicating its role in M1/M2 polarization in both EGFR-TKI-resistant NSCLC cell lines. The downregulation of CD206+ TAMs (PC9-GR: P < 0.05; HCC827-GR: P < 0.01) and the upregulation of CD86+ TAMs (PC9-GR: P < 0.001; HCC827-GR: P < 0.05) also demonstrated the reversion of suppressive TME after ZEB2 knockout in EGFR-TKI-resistant mice models. Additionally, after the intervention of MK2206, which was an Akt inhibitor, ZEB2 expression was suppressed at both low (PC9-GR: P < 0.001; HCC827-GR: P < 0.001) and high concentrations (PC9-GR: P < 0.001; HCC827-GR: P < 0.0001). Finally, the mechanism underlying ZEB2’s regulation on TAM polarization was proved to be associated with cytokine secretion. According to the results of ELISA, apart from its inducement on TGF-β1 secretion (PC9-GR: P < 0.0001; HCC827-GR: P < 0.0001), ZEB2 could directly bind to the promoter region of CSF-1 to elevate its secretion (PC9-GR: P < 0.0001; HCC827-GR: P < 0.0001). Conclusion: In EGFR-TKI-resistant NSCLC, activation of the PI3K-Akt cascade drove a marked rise in ZEB2 expression. The elevated ZEB2 increased CSF-1 and TGF-β1 release, steering macrophages toward an M2 phenotype while impeding M1 polarization. Accordingly, suppressing ZEB2 had the potential to reshape the TME and enhance the effectiveness of ICIs once EGFR-TKI resistance had emerged.
- Open Access
- 15 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 482
EGFR-Mutant Lung Adenocarcinoma Cell-Derived Exosomal miR-651-5p Induces CD8+ T Cell Apoptosis via Downregulating BCL2 Expression
Background: The efficacy of programmed cell death 1 (PD-1) or ligand 1 (PD-L1) inhibitors in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients is not satisfactory. Studies have indicated that the ratio of CD8+ tumor infiltration lymphocytes (TILs) was associated with immunotherapy efficacy; however, it was significantly lower in EGFR-mutant than wild type patients. The underlying mechanisms need to be studied. Methods: Database analysis, clinical specimens, small RNA sequencing, and single-cell sequencing were used to analyze miRNA expression and immune cell infiltration. Cell co-culture and flow cytometry were conducted to detect immune cell apoptosis. The mouse model was performed to analyze the influence of miR-651-5p antagomirs on the tumor microenvironment. Results: The miR-651-5p was found to be highly expressed in EGFR-mutant lung adenocarcinoma cell-derived exosomes, which could promote CD8+ T cell apoptosis, while the miR-651-5p inhibitor decreased the ratio of PC9-secreted exosomes and induced apoptosis. Mechanistically, the EGFR signaling pathway promoted the expression of miR-651-5p by activating the transcription factor Fos proto-oncogene (FOS) in EGFR-mutant lung adenocarcinoma cell lines. B-cell lymphoma 2 (BCL2) was the target of miR-651-5p, and miR-651-5p could promote T cell apoptosis by inhibiting BCL2 expression. In addition, the miR-651-5p antagomir increased T cell infiltration and enhanced the efficacy of the PD-1 inhibitor treating the EGFR-mutant lung adenocarcinoma humanized mouse model. Conclusions: EGFR-mutant lung adenocarcinoma promotes T cell apoptosis through exosomal miR-651-5p. miR-651-5p antagonists increase immune cell infiltration and enhance the anti-tumor effect of PD-1 inhibitor, suggesting a new combination therapy to improve the efficacy of immunotherapy in EGFR-mutant NSCLC patients.
- 15 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 482
Open AccessEGFR-Mutant Lung Adenocarcinoma Cell-Derived Exosomal miR-651-5p Induces CD8+ T Cell Apoptosis via Downregulating BCL2 Expression
Background: The efficacy of programmed cell death 1 (PD-1) or ligand 1 (PD-L1) inhibitors in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients is not satisfactory. Studies have indicated that the ratio of CD8+ tumor infiltration lymphocytes (TILs) was associated with immunotherapy efficacy; however, it was significantly lower in EGFR-mutant than wild type patients. The underlying mechanisms need to be studied. Methods: Database analysis, clinical specimens, small RNA sequencing, and single-cell sequencing were used to analyze miRNA expression and immune cell infiltration. Cell co-culture and flow cytometry were conducted to detect immune cell apoptosis. The mouse model was performed to analyze the influence of miR-651-5p antagomirs on the tumor microenvironment. Results: The miR-651-5p was found to be highly expressed in EGFR-mutant lung adenocarcinoma cell-derived exosomes, which could promote CD8+ T cell apoptosis, while the miR-651-5p inhibitor decreased the ratio of PC9-secreted exosomes and induced apoptosis. Mechanistically, the EGFR signaling pathway promoted the expression of miR-651-5p by activating the transcription factor Fos proto-oncogene (FOS) in EGFR-mutant lung adenocarcinoma cell lines. B-cell lymphoma 2 (BCL2) was the target of miR-651-5p, and miR-651-5p could promote T cell apoptosis by inhibiting BCL2 expression. In addition, the miR-651-5p antagomir increased T cell infiltration and enhanced the efficacy of the PD-1 inhibitor treating the EGFR-mutant lung adenocarcinoma humanized mouse model. Conclusions: EGFR-mutant lung adenocarcinoma promotes T cell apoptosis through exosomal miR-651-5p. miR-651-5p antagonists increase immune cell infiltration and enhance the anti-tumor effect of PD-1 inhibitor, suggesting a new combination therapy to improve the efficacy of immunotherapy in EGFR-mutant NSCLC patients.
- Open Access
- 23 December 2024
- Published by MDPI AG in Preprints.org
EGFR Mutant Lung Adenocarcinoma Cells-Derived Exosomal miR-651-5p Induces CD8+ T Cell Apoptosis via Downregulating BCL2 Expression
Background: The efficacy of programmed cell death 1 (PD-1) or ligand 1 (PD-L1) inhibitors in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients is not satisfactory. Studies have indicated that the ratio of CD8+ tumor infiltration lymphocytes (TILs) was associated with immunotherapy efficacy, however, it was significantly lower in EGFR mutant than wild-type patients. The underlying mechanisms need to be studied. Methods: Database analysis, clinical specimens, small RNA sequencing, and single-cell sequencing were used to analyze miRNA expression and immune cell infiltration. Cell co-culture and flow cytometry were conducted to detect immune cell apoptosis. The mouse model was performed to analyze the influence of miR-651-5p antagomir on the tumor microenvironment. Results: The miR-651-5p was found to be highly expressed in EGFR mutant lung adenocarcinoma cell-derived exosomes which could promote CD8+ T cell apoptosis, while miR-651-5p inhibitor decreased the ratio of PC9 secreted exosomes induced apoptosis. Mechanistically, the EGFR signaling pathway promoted the expression of miR-651-5p by activating the transcription factor FOS in EGFR-mutant lung adenocarcinoma cell lines. BCL2 was identified as the target of miR-651-5p, and miR-651-5p could promote T cell apoptosis by inhibiting BCL2 expression. Besides, miR-651-5p antagomir increased T cells infiltration and enhanced the efficacy of PD-1 inhibitor treating EGFR mutant lung adenocarcinoma in a humanized mouse model. Conclusions: EGFR mutant lung adenocarcinoma promotes T cell apoptosis through exosomal miR-651-5p. miR-651-5p antagonists increase immune cell infiltration and enhance the anti-tumor effect of PD-1 inhibitor, suggesting a potential mechanism to improve the efficacy of immunotherapy in this group.
- 23 December 2024
- Published by MDPI AG in Preprints.org
Open AccessEGFR Mutant Lung Adenocarcinoma Cells-Derived Exosomal miR-651-5p Induces CD8+ T Cell Apoptosis via Downregulating BCL2 Expression
Background: The efficacy of programmed cell death 1 (PD-1) or ligand 1 (PD-L1) inhibitors in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients is not satisfactory. Studies have indicated that the ratio of CD8+ tumor infiltration lymphocytes (TILs) was associated with immunotherapy efficacy, however, it was significantly lower in EGFR mutant than wild-type patients. The underlying mechanisms need to be studied. Methods: Database analysis, clinical specimens, small RNA sequencing, and single-cell sequencing were used to analyze miRNA expression and immune cell infiltration. Cell co-culture and flow cytometry were conducted to detect immune cell apoptosis. The mouse model was performed to analyze the influence of miR-651-5p antagomir on the tumor microenvironment. Results: The miR-651-5p was found to be highly expressed in EGFR mutant lung adenocarcinoma cell-derived exosomes which could promote CD8+ T cell apoptosis, while miR-651-5p inhibitor decreased the ratio of PC9 secreted exosomes induced apoptosis. Mechanistically, the EGFR signaling pathway promoted the expression of miR-651-5p by activating the transcription factor FOS in EGFR-mutant lung adenocarcinoma cell lines. BCL2 was identified as the target of miR-651-5p, and miR-651-5p could promote T cell apoptosis by inhibiting BCL2 expression. Besides, miR-651-5p antagomir increased T cells infiltration and enhanced the efficacy of PD-1 inhibitor treating EGFR mutant lung adenocarcinoma in a humanized mouse model. Conclusions: EGFR mutant lung adenocarcinoma promotes T cell apoptosis through exosomal miR-651-5p. miR-651-5p antagonists increase immune cell infiltration and enhance the anti-tumor effect of PD-1 inhibitor, suggesting a potential mechanism to improve the efficacy of immunotherapy in this group.
- Open Access
- 31 January 2024
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (01) , 44-52
Clinical characteristics and risk factors of non-mild outcomes in patients with Omicron variant COVID-19 in Shanghai, China
Introduction: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant rapidly appeared in Shanghai, China in early March 2022. Although a few studies have analyzed the risk factors of the severe type, identifying risk factors for non-mild COVID-19 outcomes (general/severe/critical type) which occur with radiographic evidence of pneumonia is lacking. Methodology: The COVID-19 patients admitted to a district-level designated hospital from April 26 to May 21 were enrolled in this retrospective study. The clinical manifestations and laboratory examinations were analyzed. Logistic regression was employed to evaluate risk factors for non-mild outcomes. Results: Of the 311 patients, 196 (63.0%) were mild and 115 (37.0%) were non-mild. Among them, 215 cases (69.1%) were unvaccinated. Male, ≥ 60 years age, and chronic kidney disease were risk factors of progressing to non-mild. Patients with more than two comorbidities were more likely to become non-mild, whereas two/booster doses vaccinated patients had a lower risk of developing to non-mild. The median negative conversion days (NCDs) were 12 days. Non-mild, > 2 comorbidities, delayed admission (> 3 days), and Paxlovid (Pfizer, Freiburg, Germany) treatment significantly lengthened the NCDs. Conclusions: Our results call for special concern for full and booster vaccination of the elderly, which will effectively protect from progression of COVID-19 to non-mild state. In the meantime, symptomatic COVID-19 patients should be treated as soon as possible.
- 31 January 2024
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (01) , 44-52
Open AccessClinical characteristics and risk factors of non-mild outcomes in patients with Omicron variant COVID-19 in Shanghai, China
Introduction: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant rapidly appeared in Shanghai, China in early March 2022. Although a few studies have analyzed the risk factors of the severe type, identifying risk factors for non-mild COVID-19 outcomes (general/severe/critical type) which occur with radiographic evidence of pneumonia is lacking. Methodology: The COVID-19 patients admitted to a district-level designated hospital from April 26 to May 21 were enrolled in this retrospective study. The clinical manifestations and laboratory examinations were analyzed. Logistic regression was employed to evaluate risk factors for non-mild outcomes. Results: Of the 311 patients, 196 (63.0%) were mild and 115 (37.0%) were non-mild. Among them, 215 cases (69.1%) were unvaccinated. Male, ≥ 60 years age, and chronic kidney disease were risk factors of progressing to non-mild. Patients with more than two comorbidities were more likely to become non-mild, whereas two/booster doses vaccinated patients had a lower risk of developing to non-mild. The median negative conversion days (NCDs) were 12 days. Non-mild, > 2 comorbidities, delayed admission (> 3 days), and Paxlovid (Pfizer, Freiburg, Germany) treatment significantly lengthened the NCDs. Conclusions: Our results call for special concern for full and booster vaccination of the elderly, which will effectively protect from progression of COVID-19 to non-mild state. In the meantime, symptomatic COVID-19 patients should be treated as soon as possible.
- 31 October 2023
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 18 (11) , S444
EP03.03-05 Immunological Profiling of PD-1-Treated Murine Model Reveals Meyloid-Enriched Phenotypes
- 31 October 2023
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 18 (11) , S444
EP03.03-05 Immunological Profiling of PD-1-Treated Murine Model Reveals Meyloid-Enriched Phenotypes
- Open Access
- 15 May 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (13) , 14317-14326
Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non‐small cell lung cancer
Objective: Immune checkpoint inhibitors (ICIs) or combined with chemotherapy exhibit substantial efficacy for the treatment of advanced non‐small cell lung cancer (NSCLC). However, reliable biomarkers that can monitor response to first‐line ICIs ± chemotherapy remain unclear.Methods: A total of 16 tumor tissues and 46 matched peripheral blood samples at baseline and during treatment were retrospectively collected from 19 locally advanced or metastatic NSCLC patients. The circulating tumor DNA (ctDNA) burden by tumor‐informed assay was detected to monitor and predict the therapeutic response and survival of NSCLC patients treated with first‐line ICIs or plus chemotherapy.Results: We found that ctDNA was only positively detected in one patient by tumor‐agnostic assay with a mean variant allele fraction (VAF) of 6.40%, whereas it was positively detected in three patients by tumor‐informed assay with a mean VAF of 8.83%, 0.154%, and 0.176%, respectively. Tumor‐informed assays could sensitively detect ctDNA in 93.75% (15/16) of patients. Trends in the level of ctDNA from baseline to first evaluation was consistent with the radiographic changes. There was a greater decrease in ctDNA after treatment compared with baseline in patients with partial response compared to patients with stable disease/progressive disease. Patients with over a 50% reduction in ctDNA had a significant progression‐free survival and overall survival benefit.Conclusion: The tumor‐informed assay was favorable for ctDNA detection, and early dynamic changes in plasma ctDNA may be a valuable biomarker for monitoring the efficacy and predicting the outcome in advanced NSCLC patients treated with first‐line ICIs ± chemotherapy.
- 15 May 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (13) , 14317-14326
Open AccessPersonalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non‐small cell lung cancer
Objective: Immune checkpoint inhibitors (ICIs) or combined with chemotherapy exhibit substantial efficacy for the treatment of advanced non‐small cell lung cancer (NSCLC). However, reliable biomarkers that can monitor response to first‐line ICIs ± chemotherapy remain unclear.Methods: A total of 16 tumor tissues and 46 matched peripheral blood samples at baseline and during treatment were retrospectively collected from 19 locally advanced or metastatic NSCLC patients. The circulating tumor DNA (ctDNA) burden by tumor‐informed assay was detected to monitor and predict the therapeutic response and survival of NSCLC patients treated with first‐line ICIs or plus chemotherapy.Results: We found that ctDNA was only positively detected in one patient by tumor‐agnostic assay with a mean variant allele fraction (VAF) of 6.40%, whereas it was positively detected in three patients by tumor‐informed assay with a mean VAF of 8.83%, 0.154%, and 0.176%, respectively. Tumor‐informed assays could sensitively detect ctDNA in 93.75% (15/16) of patients. Trends in the level of ctDNA from baseline to first evaluation was consistent with the radiographic changes. There was a greater decrease in ctDNA after treatment compared with baseline in patients with partial response compared to patients with stable disease/progressive disease. Patients with over a 50% reduction in ctDNA had a significant progression‐free survival and overall survival benefit.Conclusion: The tumor‐informed assay was favorable for ctDNA detection, and early dynamic changes in plasma ctDNA may be a valuable biomarker for monitoring the efficacy and predicting the outcome in advanced NSCLC patients treated with first‐line ICIs ± chemotherapy.
- Open Access
- 13 December 2022
- Published by Springer Nature in Research Square
Personalized circulating tumor DNA detection for monitoring immunotherapy efficacy in locally advanced or metastatic non-small cell lung cancer
Immune checkpoint inhibitors (ICIs) or combined with chemotherapy have shown outstanding efficacy in treatment of advanced non-small cell lung cancer (NSCLC). However, efficient biomarkers for monitoring response to first-line ICIs ± chemotherapy remain unclear. In our study, 16 tumor tissues and 46 matched peripheral blood samples at baseline and during treatment from 19 locally advanced or metastatic NSCLC patients were collected. Circulating tumor DNA (ctDNA) burden by tumor-informed assay was detected to monitor and predict therapeutic response and survival of NSCLC patients treated with first-line ICIs or plus chemotherapy. We first compared the susceptibility of tumor-informed assay and tumor-agnostic assay to detect ctDNA, and found that ctDNA was only positively detected in one patient by tumor-agnostic assay with mean variant allele fraction (VAF) of 6.40%, while positively detected in three patients by tumor-informed assay with mean VAF of 8.83%, 0.154% and 0.176%, respectively. Moreover, tumor-informed assays demonstrated sensitive ctDNA detection in 93.75% (15/16) of patients. The trend of ctDNA level from baseline to first evaluation was consistent with radiographic changes. The decrease in ctDNA after treatment compared with baseline was more in patients with partial response than in patients with stable disease/progressive disease. Patients with more than 50% reduction had a significant progression-free survival and overall survival benefit. Our findings suggested that tumor-informed assay turned to be a better option for ctDNA detection, and plasma early ctDNA dynamic changes could be a valuable biomarker for monitoring efficacy and outcome prediction in advanced NSCLC patients treated with first-line ICIs ± chemotherapy.
- 13 December 2022
- Published by Springer Nature in Research Square
Open AccessPersonalized circulating tumor DNA detection for monitoring immunotherapy efficacy in locally advanced or metastatic non-small cell lung cancer
Immune checkpoint inhibitors (ICIs) or combined with chemotherapy have shown outstanding efficacy in treatment of advanced non-small cell lung cancer (NSCLC). However, efficient biomarkers for monitoring response to first-line ICIs ± chemotherapy remain unclear. In our study, 16 tumor tissues and 46 matched peripheral blood samples at baseline and during treatment from 19 locally advanced or metastatic NSCLC patients were collected. Circulating tumor DNA (ctDNA) burden by tumor-informed assay was detected to monitor and predict therapeutic response and survival of NSCLC patients treated with first-line ICIs or plus chemotherapy. We first compared the susceptibility of tumor-informed assay and tumor-agnostic assay to detect ctDNA, and found that ctDNA was only positively detected in one patient by tumor-agnostic assay with mean variant allele fraction (VAF) of 6.40%, while positively detected in three patients by tumor-informed assay with mean VAF of 8.83%, 0.154% and 0.176%, respectively. Moreover, tumor-informed assays demonstrated sensitive ctDNA detection in 93.75% (15/16) of patients. The trend of ctDNA level from baseline to first evaluation was consistent with radiographic changes. The decrease in ctDNA after treatment compared with baseline was more in patients with partial response than in patients with stable disease/progressive disease. Patients with more than 50% reduction had a significant progression-free survival and overall survival benefit. Our findings suggested that tumor-informed assay turned to be a better option for ctDNA detection, and plasma early ctDNA dynamic changes could be a valuable biomarker for monitoring efficacy and outcome prediction in advanced NSCLC patients treated with first-line ICIs ± chemotherapy.
- Top Cited PapersOpen Access
- 21 July 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-10
Non-invasive early detection of cancer four years before conventional diagnosis using a blood test
Early detection has the potential to reduce cancer mortality, but an effective screening test must demonstrate asymptomatic cancer detection years before conventional diagnosis in a longitudinal study. In the Taizhou Longitudinal Study (TZL), 123,115 healthy subjects provided plasma samples for long-term storage and were then monitored for cancer occurrence. Here we report the preliminary results of PanSeer, a noninvasive blood test based on circulating tumor DNA methylation, on TZL plasma samples from 605 asymptomatic individuals, 191 of whom were later diagnosed with stomach, esophageal, colorectal, lung or liver cancer within four years of blood draw. We also assay plasma samples from an additional 223 cancer patients, plus 200 primary tumor and normal tissues. We show that PanSeer detects five common types of cancer in 88% (95% CI: 80–93%) of post-diagnosis patients with a specificity of 96% (95% CI: 93–98%), We also demonstrate that PanSeer detects cancer in 95% (95% CI: 89–98%) of asymptomatic individuals who were later diagnosed, though future longitudinal studies are required to confirm this result. These results demonstrate that cancer can be non-invasively detected up to four years before current standard of care.
- 21 July 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-10
Top Cited PapersOpen AccessNon-invasive early detection of cancer four years before conventional diagnosis using a blood test
Early detection has the potential to reduce cancer mortality, but an effective screening test must demonstrate asymptomatic cancer detection years before conventional diagnosis in a longitudinal study. In the Taizhou Longitudinal Study (TZL), 123,115 healthy subjects provided plasma samples for long-term storage and were then monitored for cancer occurrence. Here we report the preliminary results of PanSeer, a noninvasive blood test based on circulating tumor DNA methylation, on TZL plasma samples from 605 asymptomatic individuals, 191 of whom were later diagnosed with stomach, esophageal, colorectal, lung or liver cancer within four years of blood draw. We also assay plasma samples from an additional 223 cancer patients, plus 200 primary tumor and normal tissues. We show that PanSeer detects five common types of cancer in 88% (95% CI: 80–93%) of post-diagnosis patients with a specificity of 96% (95% CI: 93–98%), We also demonstrate that PanSeer detects cancer in 95% (95% CI: 89–98%) of asymptomatic individuals who were later diagnosed, though future longitudinal studies are required to confirm this result. These results demonstrate that cancer can be non-invasively detected up to four years before current standard of care.